Stock events for Gossamer Bio, Inc. (GOSS)
Gossamer Bio's stock price has experienced significant volatility and a substantial decline in the past six months. As of March 6, 2026, the share price was $0.50, representing a 58.62% decline over the past year and an approximate 80.05% decrease over the past six months. A major event impacting the stock was the announcement in February 2026 of the Phase 3 PROSERA study results, which did not meet its prespecified primary endpoint statistical threshold, leading to a sharp decline in the stock price and subsequent downgrades from several brokerages.
Demand Seasonality affecting Gossamer Bio, Inc.’s stock price
As a clinical-stage biopharmaceutical company, Gossamer Bio, Inc. primarily generates revenue through collaboration agreements and milestone payments rather than commercial product sales. Therefore, there is no readily available information or indication of demand seasonality for its products and services. The company's financial performance is more closely tied to its progress in clinical trials and strategic partnerships.
Overview of Gossamer Bio, Inc.’s business
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in immunology, inflammation, and oncology. Their primary product candidate is seralutinib, an investigational inhaled small molecule inhibitor in Phase III clinical trials for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Other pipeline products include GB004 for inflammatory bowel disease, GB1275 for oncology indications, and GB001 for eosinophilic asthma and other allergic conditions.
GOSS’s Geographic footprint
Gossamer Bio, Inc. is headquartered in San Diego, California, and primarily focuses on seralutinib development and commercialization in the United States. They have a global collaboration agreement with the Chiesi Group for the joint development of seralutinib in PAH and PH-ILD, with Gossamer Bio leading the global development.
GOSS Corporate Image Assessment
Gossamer Bio's brand reputation has been significantly impacted by the Phase 3 PROSERA study results for seralutinib in February 2026. The trial's failure to meet its primary endpoint led to analyst downgrades and a substantial drop in the company's stock price. This event has raised questions regarding the regulatory path for seralutinib and the company's financial viability, particularly concerning its convertible debt, with the company described as quickly burning through cash.
Ownership
Gossamer Bio, Inc. has a mixed ownership structure comprising institutional, insider, and retail investors. Approximately 79.92% of the company's stock is held by institutional shareholders, 15.24% by Gossamer Bio insiders, and 4.84% by retail investors. Major institutional owners include NEA Management Company, LLC, BlackRock, Inc., Octagon Capital Advisors LP, The Vanguard Group, Inc., State Street Corp, Arch Venture Corp / Arch Venture Partners, L.P., Samsara BioCapital, LLC, Siren, L.L.C., 683 Capital Management, LLC, and Hillhouse Capital Advisors, Ltd. / Hillhouse Investment Management, Ltd. Omega Fund V LP is the largest individual shareholder, owning 13.51 million shares, representing 5.84% of the company.
